Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for PULM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 2.557M
March 31, 2026 3.591M
December 31, 2025 3.81M
September 30, 2025 4.733M
June 30, 2025 5.604M
March 31, 2025 7.147M
December 31, 2024 8.947M
September 30, 2024 10.92M
June 30, 2024 13.31M
March 31, 2024 19.02M
December 31, 2023 18.00M
September 30, 2023 19.88M
June 30, 2023 23.45M
March 31, 2023 27.01M
December 31, 2022 31.11M
September 30, 2022 35.05M
June 30, 2022 38.44M
March 31, 2022 42.76M
December 31, 2021 47.45M
September 30, 2021 45.19M
June 30, 2021 53.09M
March 31, 2021 56.65M
December 31, 2020 23.14M
September 30, 2020 23.50M
June 30, 2020 13.88M
Date Value
March 31, 2020 6.936M
December 31, 2019 11.02M
September 30, 2019 14.73M
June 30, 2019 18.09M
March 31, 2019 10.20M
December 31, 2018 11.84M
September 30, 2018 12.63M
June 30, 2018 16.80M
March 31, 2018 7.528M
December 31, 2017 10.14M
September 30, 2017 12.78M
June 30, 2017 15.79M
March 31, 2017 15.90M
December 31, 2016 8.761M
September 30, 2016 17.47M
June 30, 2016 20.15M
March 31, 2016 28.17M
December 31, 2015 32.61M
September 30, 2015 35.91M
June 30, 2015 39.31M
March 31, 2015 -44.99M
December 31, 2014
September 30, 2014
June 30, 2014
March 31, 2014 14.63M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. 597.21M
Corcept Therapeutics, Inc. 705.78M
Veru, Inc. 28.38M
Johnson & Johnson 84.97B
Eli Lilly & Co. 33.88B

Shareholders Equity (Quarterly) Related Metrics